See more : Retty Inc. (7356.T) Income Statement Analysis – Financial Results
Complete financial analysis of Bonus BioGroup Ltd. (BBIXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bonus BioGroup Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Nabors Energy Transition Corp. II Class A Ordinary Shares (NETD) Income Statement Analysis – Financial Results
- Windon Energy Group AB (WEG.ST) Income Statement Analysis – Financial Results
- Conroy Gold and Natural Resources plc (CGDNF) Income Statement Analysis – Financial Results
- PT Urban Jakarta Propertindo Tbk. (URBN.JK) Income Statement Analysis – Financial Results
- Adecoagro S.A. (0DWL.L) Income Statement Analysis – Financial Results
Bonus BioGroup Ltd. (BBIXF)
About Bonus BioGroup Ltd.
Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. It develops tissue-regenerating bone grafts from cells derived from the patient's own cells for the treatment of skeletal disorders, such as bone trauma and arthritis. The company's products include BonoFill injectable bone graft that is suitable for bone repair applications, including jaw bone cysts; and BonoFill pre-designed bone graft, which is used to repair large and segmental bone defects. Its products in pipeline comprise bone grafts for maxillofacial and orthopedic applications; novel nanomaterials technology for tissue regeneration; and large vascularized bone grafts. The company was formerly known as Oceana Advanced Industries Ltd. and changed its name to Bonus BioGroup Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 3.37M | 4.10M | 1.61M | 1.33M | 2.14M | 1.34M | 1.14M | 904.00K | 1.35M | 608.00K | 169.00K |
| Gross Profit | 0.00 | -3.37M | -4.10M | -1.61M | -1.33M | -2.14M | -1.34M | -1.14M | -904.00K | -1.35M | -608.00K | -169.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.61M | 21.31K | 20.79K | 11.36K | 11.08M | 10.82M | 10.89M | 6.90M | 9.37M | 9.44M | 6.08M | 0.00 |
| General & Administrative | 11.18M | 5.46M | 31.34M | 2.80M | 2.39M | 2.10M | 3.31M | 3.03M | 4.55M | 2.23M | 2.56M | 2.64M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 343.00K | 258.00K | 676.00K | 251.00K | 244.00K | 176.00K | 157.00K |
| SG&A | 11.18M | 5.46M | 31.34M | 2.80M | 2.39M | 2.10M | 3.31M | 3.03M | 4.55M | 2.23M | 2.56M | 2.64M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9.24M |
| Operating Expenses | 29.79M | 33.68M | 60.64M | 17.84M | 20.91M | 18.45M | 18.79M | 14.82M | 12.49M | 9.85M | 9.14M | 8.61M |
| Cost & Expenses | 29.79M | 37.05M | 64.74M | 19.44M | 20.91M | 18.45M | 20.13M | 15.96M | 13.40M | 11.20M | 9.75M | 8.78M |
| Interest Income | 879.00 | 7.28M | 164.00K | 0.00 | 0.00 | 79.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 891.00K | 569.00K | 408.00K | 460.00K | 364.00K | 67.00K | 83.00K | 61.00K | 27.00K | 24.00K | 10.00K |
| Depreciation & Amortization | 1.65M | 2.66M | 1.48M | 1.07M | 1.08M | 197.00K | 163.00K | 410.00K | 489.00K | 459.00K | 223.00K | 4.00K |
| EBITDA | -28.14M | -35.60M | -63.26M | -18.38M | -19.83M | -18.25M | -19.97M | -15.55M | -12.91M | -10.74M | -9.53M | -18.02M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.79M | -37.05M | -64.74M | -19.44M | -20.91M | -18.45M | -20.13M | -15.96M | -13.40M | -11.18M | -9.68M | -17.96M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.26M | -1.66M | -25.34M | -2.58M | -1.33M | -285.00K | -67.00K | -83.00K | -61.00K | -27.00K | -24.00K | -10.00K |
| Income Before Tax | -28.53M | -38.70M | -90.08M | -22.02M | -22.24M | -18.74M | -20.20M | -16.05M | -13.46M | -11.21M | -9.70M | -17.97M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 7.26M | -3.79M | -15.00K | -195.00K | 79.00K | 0.00 | 119.00K | 0.00 | -20.00K | -72.00K | -56.00K |
| Net Income | -28.53M | -38.70M | -90.08M | -22.02M | -22.24M | -18.74M | -20.20M | -16.05M | -13.46M | -11.21M | -9.70M | -17.97M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.06 | -0.16 | -0.06 | -0.07 | -0.07 | -0.08 | -0.07 | -0.06 | -0.06 | -0.06 | -0.15 |
| EPS Diluted | -0.02 | -0.06 | -0.16 | -0.06 | -0.07 | -0.07 | -0.08 | -0.07 | -0.06 | -0.06 | -0.06 | -0.15 |
| Weighted Avg Shares Out | 1.17B | 621.08M | 579.12M | 393.93M | 306.25M | 283.68M | 259.56M | 233.54M | 214.40M | 201.67M | 174.46M | 120.76M |
| Weighted Avg Shares Out (Dil) | 1.17B | 621.08M | 579.12M | 393.93M | 306.25M | 283.68M | 259.56M | 233.54M | 214.40M | 201.67M | 174.46M | 120.76M |
Source: https://incomestatements.info
Category: Stock Reports